

Benjamin Weber, PhD, EMBA, MStat, BPharm

Executive Director & Head of US Pharmacometrics
Translational Medicine & Clinical Pharmacology
Boehringer Ingelheim, Ridgefield, CT

Contact

Phone: +1 475 237 8060
Private E-Mail: benjamin.weber@bweber.net
Business E-Mail: benjamin.weber@boehringer-ingelheim.com
Webpage: <http://bweber.net>

Summary

Benjamin is a business-minded and purpose driven leader in the pharmaceutical industry with a strong scientific background and cross-cultural experience. Through leadership roles and project assignments, he has gained experience across the pharmaceutical industry value chain and in all phases of drug development in the therapeutic areas respiratory, immunology, cardiovascular, metabolism and central nervous system.

At Boehringer Ingelheim (BI), Benjamin is leading a group of quantitative clinical pharmacologists that accelerate and streamline drug development by applying model-informed drug development approaches. His senior group members lead early clinical development teams and are responsible for delivering overall drug development strategies including biomarker and clinical pharmacology strategies to senior management committees. Previously, Benjamin was Head of Translational Medicine & Clinical Pharmacology Respiratory at BI.

Benjamin holds a Professional Degree in Pharmacy from University of Tuebingen, a Master of Statistics from University of Florida, an Executive Master of Business Administration from Quantic School of Business and Technology and a PhD in Pharmaceutical Sciences from University of Florida.

His transferable skills include making better decisions, asking the right questions at the right time, developing and leading individuals and groups, as well as developing and executing strategies in the pharmaceutical industry.

Benjamin was recognized with outstanding young alumni award "40 Gators Under 40" by the University of Florida. He published multiple articles in peer-reviewed journals and received invitations to present at academic institutions and international conferences.

He has a successful track record of applying situational leadership principles with direct reports and in a matrix environment. Benjamin is strongly convinced and a role model that a healthy work-life-balance is key for sustainable career success.

Current Positions

Executive Director & Head of US Pharmacometrics

Translational Medicine & Clinical Pharmacology

Jun 2019 – Present Executive Director

Oct 2015 – May 2019 Director

Boehringer Ingelheim, Ridgefield, CT, USA

- Leads a global group of quantitative clinical pharmacologists that accelerate and streamline drug development by applying model-informed drug development approaches in the therapeutic areas respiratory, immunology, central nervous system, cardiovascular and metabolism. Senior group members lead early clinical development teams and are responsible for delivering overall drug development strategies including biomarker and clinical pharmacology strategies to senior management committees.
- Co-led a project how microsegmentation and microtargeting could be leveraged in direct-to-consumer marketing that was sponsored by Human Pharma Leadership Team
- Led development and implementation of global pharmacometrics strategy

Adjunct Faculty - Courtesy Assistant Professor

November 2013 – present

College of Pharmacy, University of Florida, Gainesville, FL

- Delivers lectures and seminars for PhD students, post-docs, and faculty
-

Professional Experience

Head of Translational Medicine & Clinical Pharmacology Respiratory

Apr 2017 – Jun 2019

Boehringer Ingelheim, Ridgefield, CT

- Oversaw biomarker and clinical pharmacology strategies on an indication and project level
- As voting member in Therapeutic Area Leadership Committee, contributed to portfolio and project level decision-making across the pharmaceutical industry value chain
- As voting member in Clinical Expert Committee, contributed to the endorsement of clinical development plans, clinical trial protocols and clinical trial results
- Oversaw budgets for all early clinical development trials
- Led a strategic initiative on enhancing the efficiency in drug discovery and development

Senior Associate Director, Pharmacometrics

Jul 2014 - Sep 2015 Senior Associate Director

Apr 2013 - Jun 2014 Associate Director

Boehringer Ingelheim, Biberach an der Riss, Germany

- As member of drug development project teams, contributed to drug development strategies as well as accelerated and streamlined drug development by applying model-informed drug development approaches strategically and hands-on in the therapeutic area respiratory
- Led regulatory submission relevant dose-exposure-response analyses comprising disease progress modeling, time-to-event analysis, and covariate analysis for nintedanib in idiopathic pulmonary fibrosis
- Evaluated of approaches, models, and software programs for modeling and simulation of respiratory diseases including pharmaceutical intervention and pharmaco-economics

Owner & Consultant

Aug 2012 – Mar 2013

Development Strategies and Statistical Analysis for Orally Inhaled Drug Products, Langenau, Germany

- Provided expert knowledge on pre-clinical and clinical drug development of generic orally inhaled drug products as well as the application of the modified chi-square ratio statistic and other statistical approaches for equivalence testing of cascade impactor data

Research Assistant

Jan 2009 – Mar 2013

Department of Pharmaceutics, University of Florida, Gainesville, FL

- Led regulatory submission relevant POPPK analysis for a novel cardiovascular compound in collaboration with other researchers from Department of Pharmaceutical Sciences and the Center of Pharmacometrics and Systems Pharmacology
- Developed freely available semi-mechanistic PK model for simulating clinical trials for inhaled drugs leading to a publication in the AAPS Journal

ORISE Fellow

May 2010 - Aug 2010 and May 2011 - Aug 2011

Food and Drug Administration, Rockville, MD

- Developed modified chi-square ratio statistic
 - Evaluated methods for testing equivalence in aerodynamic particle size distribution
 - Published to four original research articles in the AAPS Journal and Respiratory Drug Delivery and was invited to give talks and poster presentations at scientific conferences
-

Education

PhD in Pharmaceutical Sciences

University of Florida, College of Pharmacy, Gainesville, FL

Executive Master of Business Administration

Quantic School of Business and Technology, Washington, DC

Master of Statistics

University of Florida, College of Liberal Arts & Sciences, Gainesville, FL

Professional Degree in Pharmacy

University of Tuebingen, Tuebingen, Germany

B.S. in Pharmacy

University of Tuebingen, Tuebingen, Germany

Transferable Skills

- Better decision-making
- Asking the right questions at the right time
- People and group development
- Developing and implementing strategies in the pharmaceutical industry
- Navigating through complex and uncertain situations with calmness and a sense of urgency

Areas of Expertise

- Decision-making, R&D efficiency and model informed drug discovery and development (MID3)
- Clinical drug development with a focus on clinical pharmacology, pharmacometrics, biomarkers and translational medicine
- Respiratory diseases, diseases of the immune system & inhalation
- Pharmacokinetics and pharmacodynamics

Software Packages

Pharmacometrics and Statistics

- Proficient in NONMEM, R, Monolix, PsN, Xpose, SAS, Phoenix WinNonLin and NLME
- Basic knowledge in GastroPlus, PKSim, SimCyp, SimBiology, Berkeley Madonna

Project Management

- Liquid Planner

Applications

- Microsoft Word, Excel, PowerPoint, Tex/Latex
-

Seminars and Workshops

Leadership

- **Global Development Center**, Korn Ferry, September 2018, Danbury, CT
- Exposure and More Exposure - **Global Leadership Workshop for Boehringer Ingelheim's Future International Leaders**, November 2016 and January 2017, **IESE Business School**, Barcelona, Spain
- One-week **leadership seminar** including training in presence and effect, one-to-one communication, and managing productivity, August 2014, **ComTeam**, Gmund am Tergernsee, Germany

Clinical Pharmacology and Pharmacometrics

- Getting Started with **Bayesian PK/PD Modeling Using Stan**: Practical use of Stan and R for PKPD applications, October 2015, MetrumRG, Arlington, VA
- Two-day hands-on workshop in **model based meta-analysis**, October 2014, Quantitative Solutions, Biberach, Germany
- Two-day hand-on workshop in **covariate modeling techniques in NONMEM**, October 2013, Mats Karlsson, Biberach, Germany
- **New and Advanced Features of NONMEM 7** Workshop, September 2013, Robert Bauer, Columbia, MD,
- Modeling Biologics with **Target-Mediated Disposition**, September 2013, Leonid and Ekaterina Gibiansky, Columbia, MD
- Two-day hands-on workshop in **PKSim and MoBI**, June 2013, Bayer Technology Services, , Biberach, Germany

Publications

1. Tang F, Weber B, Stowasser S, Korell J. **Parametric Time-to-Event Model for Acute Exacerbations in Idiopathic Pulmonary Fibrosis**. CPT Pharmacometrics Syst Pharmacol. 2020; 9: 87-95
2. Geng J, Lu S, Kurup S, Weber B, Ting N. **Pharmacokinetics-Guided Dose Allocation in Comparison with Binary Dose Spacing**. Stat Biosci. 2019; 11: 677-93
3. Sharma A, Weber B, Meibohm B. **Long Pulmonary Residence Time and Plasma Half-Life of Tiotropium: Implications for Pharmacokinetic Bioequivalence Studies**. Clin Drug Investig. 2017; 37: 705
4. Sharma A, Kerstjens HA, Aalbers R, Moroni-Zentgraf P, Weber B, Dahl R. **Pharmacokinetics of tiotropium administered by Respimat(R) in asthma patients: Analysis of pooled data from phase II and III clinical trials**. Pulm Pharmacol Ther. 2016;42: 25-32
5. Nguyen TH, Mouksassi MS, Holford N, Al-Huniti N, Freedman I, Hooker AC, John J, Karlsson MO, Mould DR, Perez Ruixo JJ, Plan EL, Savic R, van Hasselt JG, Weber B, Zhou C, Comets E, Mentre F. **Model evaluation of continuous data pharmacometric models: Metrics and graphics**. CPT Pharmacometrics Syst Pharmacol. 2016;6: 87-109
6. Weber B, Borghardt JM, Parra-Guillen ZP, Sharma A, Retlich S, Staab A, Troconiz IF. **Tiotropium Pharmacokinetics and Pharmacodynamics - What are Drivers for Systemic Levels and Local Pulmonary Responses?** Respiratory Drug Delivery 2016. 2016;1:45-54.

7. Borghardt JM, Weber B, Staab A, Kunz C, Kloft C. **Model-based evaluation of pulmonary pharmacokinetics in asthmatic and COPD patients after oral olodaterol inhalation.** Br J Clin Pharmacol. 2016;82:739-53.
8. Borghardt JM, Weber B, Staab A, Kunz C, Formella S, Kloft C. **Investigating pulmonary and systemic pharmacokinetics of inhaled olodaterol in healthy volunteers using a population pharmacokinetic approach.** Br J Clin Pharmacol. 2016;81:538-52.
9. Sharma A, Weber B, Wein M, Hallmann C, Meibohm B. **Essential criteria for pharmacokinetic studies supporting bioequivalence of inhaled tiotropium bromide products.** Clin Pharmacol Drug Dev. 2016;5:52-6.
10. Weber B, Hochhaus G. **A Systematic Analysis of the Sensitivity of Plasma Pharmacokinetics to Detect Differences in the Pulmonary Performance of Inhaled Fluticasone Propionate Products Using a Model-Based Simulation Approach.** AAPS J. 2015;17:999-1010.
11. Weber B, Lee SL, Delvadia R, Lionberger R, Li BV, Tsong Y, Hochhaus G. **Application of the modified chi-square ratio statistic in a stepwise procedure for cascade impactor equivalence testing.** AAPS J. 2015;17:370-9.
12. Borghardt JM, Weber B, Staab A, Kloft C. **Pharmacometric Models for Characterizing the Pharmacokinetics of Orally Inhaled Drugs.** AAPS J. 2015;17:853-70.
13. Borghardt JM, Weber B, Staab A, Kloft C. **Impact of Pulmonary Dissolution and Pulmonary Absorption Processes on the Pulmonary and Systemic Pharmacokinetics of Inhaled Drugs: An In Silico Analysis.** RDD Europe 2015. 2015;2:299-304.
14. Weber B, Troconiz IF, Borghardt JM, Staab A, Sharma A. **Model-Based Evaluation of Single and Multiple Dose Pharmacokinetics of Inhaled Tiotropium in Healthy Volunteers and Implications for Systemic Exposure Studies.** RDD Europe 2015. 2015;2:249-54.
15. Leiner S, Weber B. **Is the EMA Guideline on Therapeutic Equivalence of Inhalation Products Up to Date?** RDD Europe 2015. 2015;2:245-8.
16. Hurtado FK, Weber B, Derendorf H, Hochhaus G, Dalla Costa T. **Population pharmacokinetic modeling of the unbound levofloxacin concentrations in rat plasma and prostate tissue measured by microdialysis.** Antimicrob Agents Chemother. 2014;58:678-86.
17. Borghardt JM, Weber B, Staab A, Kunz C, Schiewe J, Kloft C. **Expanding the Mechanistic Knowledge About Pulmonary Absorption Processes Using a Population Pharmacokinetic Model for Inhaled Olodaterol.** Respiratory Drug Delivery 2014. 2014;2:417-22.
18. Weber B, Lee SL, Lionberger R, Li BV, Tsong Y, Hochhaus G. **A sensitivity analysis of the modified chi-square ratio statistic for equivalence testing of aerodynamic particle size distribution.** AAPS J. 2013;15:465-76.
19. Weber B, Hochhaus G, Adams W, Lionberger R, Li B, Tsong Y, Lee SL. **A Stability Analysis of a Modified Version of the Chi-Square Ratio Statistic: Implications for Equivalence Testing of Aerodynamic Particle Size Distribution.** AAPS J. 2013;15:1-9.
20. Weber B, Hochhaus G. **A pharmacokinetic simulation tool for inhaled corticosteroids.** AAPS J. 2013;15:159-71.
21. Scherliess R, Buske S, Young K, Weber B, Rades T, Hook S. **In vivo evaluation of chitosan as an adjuvant in subcutaneous vaccine formulations.** Vaccine. 2013;31:4812-9.
22. Weber B, Adams W, Lionberger R, Li B, Tsong Y, Hochhaus G, Lee SL. **Evaluation of Statistical Methods for Determining Equivalence of Aerodynamic Particle Size Distribution.** Respiratory Drug Delivery 2012. 2012;3:803-8.

23. Haug KG, Weber B, Hochhaus G, Butterweck V. **Nonlinear pharmacokinetics of visnagin in rats after intravenous bolus administration.** Eur J Pharm Sci. 2012;45:79-89.
 24. Haug KG, Weber B, Hochhaus G, Butterweck V. **Pharmacokinetic evaluation of visnagin and Ammi visnaga aqueous extract after oral administration in rats.** Planta Med. 2012;78:1831-6.
 25. Wu K, Blomgren AL, Ekholm K, Weber B, Edsbaecker S, Hochhaus G. **Budesonide and ciclesonide: effect of tissue binding on pulmonary receptor binding.** Drug Metab Dispos. 2009;37:1421-6.
-

Invited Talks

1. Pharmacometrics at Boehringer Ingelheim, **Uppsala University, Department of Pharmaceutical Biosciences**, May 2017, Uppsala, Sweden
 2. Tiotropium Pharmacokinetics and Pharmacodynamics - What are Drivers for Systemic Levels and Local Pulmonary Responses? **Respiratory Drug Delivery 2016**, April 2016, Scottsdale, Arizona
 3. The Pulmonary Fate of Inhaled Drugs – What Can We Learn From Plasma Pharmacokinetics?, **10th Global Gator Symposium: New Developments in Clinical Pharmacy and Clinical Pharmacology**, June 2015, Utrecht, The Netherlands
 4. Pharmacometrics in Clinical Drug Development, **Christian-Albrechts-Universität, Abteilung fuer Pharmazeutische Technologie und Biopharmazie**, January 2015, Kiel, Germany
 5. Time-to-event models in clinical drug development, **GPEN 2014**, August 2014, Helsinki, Finland
 6. The Modified Chi-Square Ratio Statistic for Equivalence Testing of Aerodynamic Particle Size Distribution, **Orlando Inhalation Conference**, March 2014, Orlando, FL
 7. Introduction to Pharmacometrics, **Christian-Albrechts-Universität, Abteilung fuer Pharmazeutische Technologie und Biopharmazie**, January 2014, Kiel, Germany
 8. Current and Future Statistical Approaches for Cascade Impactor Studies for Inhalation Products, **AAPS Workshop: Inhaled Drugs Products: Current Practices and the Future of in vitro Testing Technologies and Regulation**, September 2013, Rockville, MD
 9. Pharmacokinetics and Pharmacodynamics of Inhaled Drugs, **Christian-Albrechts-Universität, Abteilung fuer Pharmazeutische Technologie und Biopharmazie**, January 2013, Kiel, Germany
 10. PKPD Modeling and Simulation, **University of Southern Denmark, Department of Physics, Chemistry and Pharmacy**, December 2011, Odense, Denmark
 11. Bioequivalence of Orally Inhaled Drug Products - Comparative Analysis of in vitro Cascade Impactor Data, **Food and Drug Administration, Center of Drug Evaluation and Research**, October 2011, Silver Spring, MD
 12. In vitro and in vivo methods for demonstration of bioequivalence of orally inhaled drug products with emphasis on inhaled corticosteroids, **2nd Annual CTSI Trainee and Pilot Award Research Day, Clinical Translational Science Institute**, June 2011, University of Florida, Gainesville, FL
-

Poster Presentations

1. Vaidya T, Weber B, Stowasser S, Korell J. **Model-based population analysis of disease progression in idiopathic pulmonary fibrosis.** 2020 ASCPT Annual Meeting; Houston, TX.
2. Kluwe F, Maas M, Hennige A, Weber B, Kloft C. **How predictive is short-term body-weight loss in the longer term for decision making during clinical drug development?** 2019 ACoP10; Orlando, FL.

3. Tang F, Weber B, Stowasser S, Korell J. **Time-to-event model for acute exacerbations in idiopathic pulmonary fibrosis (IPF)**. 2019 ASCPT Annual Meeting, Washington, DC.
4. Friedrich C, Weber B, Pryor M, Witt C, Borghardt J, Disse B, Dallinger C, Gupta A, Jung B, Fowler A, Singh D. **Development of the Respiratory PhysioPD (R) Platform, a QSP Model to Investigate Biological Mechanisms Underlying Bronchoconstriction**. 2018 ACoP9; San Diego, CA.
5. Schmid U, Weber B, Dallinger C, Richeldi L, Hallmann C, Raghu G, Freiwald M. **Relationship between nintedanib exposure, clinical efficacy and adverse events in patients with idiopathic pulmonary fibrosis (IPF)**. 2016 ACoP7; Bellevue, WA.
6. Schmid U, Weber B, Dallinger C, Richeldi L, Hallmann C, Raghu G, Freiwald M. **Relationship between nintedanib exposure, patient characteristics and clinical efficacy in patients with idiopathic pulmonary fibrosis**. 2016 ATS Congress; San Francisco, CA.
7. Schmid U, Weber B, Dallinger C, Luca Richeldi, Hallmann C, Raghu G, Freiwald M. **Relationship between nintedanib exposure and adverse events in patients with idiopathic pulmonary fibrosis**. ERS International Congress 2016; London, United Kingdom.
8. Bateman E, Mackie A, Benediktus E, Schepers C, Kim JM, Tadayasu Y, Lee G, Wood C, Weber B. **Safety, pharmacokinetics and pharmacodynamics of BI 1060469, a novel oral CRTH2 antagonist**. ERS International Congress 2016; London, UK.
9. Weber B, Borghardt JM. **New Insights in the Pulmonary Fate of Inhaled Drugs**. 2015 PAGE Meeting; Hersonissos, Greece.
10. Sharma A, Weber B, Stopfer P, Borghardt JM, Rapp B, Schmid M, Hallmann C, Moroni-Zentgraf P. **Tiotropium Pharmacokinetics in Patients with Asthma - A Pooled Analysis**. 2015 ACCP Meeting; San Francisco, CA.
11. Schilling U, Miesler T, Weber B, Hochhaus G. **A Semi-Mechanistic Model for Predicting the Nasal and Plasma Pharmacokinetics of Intranasal Corticosteroids**. 2015 ACCP Meeting; San Francisco, CA.
12. Miesler T, Schilling U, Weber B, Hochhaus G. **An open-source, user-friendly simulation tool to predict the pharmacokinetics of inhaled corticosteroids**. 2015 ACCP Meeting; San Francisco, CA.
13. Borghardt JM, Weber B, Staab A, Kunz C, Schiewe J, Kloft C. **The physiological interpretation of population pharmacokinetic modelling results for inhaled olodaterol**. 2015 PAGE Meeting; Hersonissos, Greece.
14. Borghardt JM, Weber B, Staab A, Kloft C. **A New Parameterisation to Describe Parallel Absorption Processes After Drug Inhalation**. 2015 PAGE Meeting; Hersonissos, Greece.
15. Parra-Guillen Z, Weber B, Sharma A, Freijer J, Retlich S, Borghardt J, Troconiz I. **Population Pharmacokinetic Analysis of Tiotropium in Healthy Volunteers after Intravenous Administration and Inhalation**. 2014 ACoP Las Vegas, NV.
16. Borghardt J, Weber B, Staab A, Kunz C, Schiewe J, Kloft C. **The physiological interpretation of population pharmacokinetic modelling results for inhaled olodaterol**. PAGE 2014; Alicante, Spain.
17. Zhao L, Weber B, Hochhaus G. **A Simulation Tool for Evaluating EMAs Regulatory PK Limits for Bioequivalence Testing of Inhaled Corticosteroids**. 2013 ACCP Meeting; Bethesda, MD.
18. Kandala B, Weber B, Winner L, Hochhaus G. **Evaluation of the Feasibility of Pharmacodynamic Bioequivalence Studies of Inhaled Corticosteroids through Monte Carlo Simulations**. ISAM 2013; Chapel Hill, NC.

19. Kandala B, Weber B, Winner L, Hochhaus G. **Power Calculations for Pharmacodynamic Crossover Studies Conducted to establish Bioequivalence of Inhaled Corticosteroids Through Monte Carlo Simulations.** 2013 ACoP; Ft. Lauderdale, FL.
 20. Kandala B, Weber B, Joseph R, Maas B, Hochhaus G. **A New Simulation Model to Assess the Power of Pharmacodynamic Crossover Studies Conducted to Establish Bioequivalence of Orally Inhaled Drug Products.** 2013 ACCP Meeting; Bethesda, MD.
 21. Hurtado F, Zimmermann E, Weber B, Derendorf H, Dalla Costa T. **Free Levooxacin Concentrations in Prostate and Lung Modeled by a Population Pharmacokinetic Approach.** 7th International Symposium on Microdialysis; Poitiers, France.
 22. Weber B, Hochhaus G. **A Clinical Trial Simulation Tool for the Suppression of the Endogenous Cortisol Release after Administration of Inhaled Corticosteroids.** 2012 GPEN Meeting Melbourne, Australia.
 23. Hurtado F, Weber B, Derendorf H, Dalla Costa T. **Population Pharmacokinetic Modeling of the Unbound Levooxacin Concentrations in Plasma and Prostate Tissue Measured by Microdialysis in Rats.** 4th Meeting of the Pharmaceutical Sciences Graduate Program; Porto Alegre, Brazil.
 24. Haug KG, Weber B, Derendorf H, Butterweck V. **Characterization of the pharmacokinetic properties of visnagin and Ammi visnaga water extract following oral administration in rats.** DPhG Jahrestagung 2012; Greifswald, Germany.
 25. Weber B, Adams W, Lionberger R, Li B, Tsong Y, Hochhaus G, Lee S. **Evaluation of Statistical Methods for Determining Equivalence of Aerodynamic Particle Size Distribution.** 2011 AAPS Annual Meeting; Washington, DC.
 26. Weber B, Goyal N, Kandala B, Hochhaus G. **Simulation-based evaluation of tmax as a pharmacokinetic parameter to assess bioequivalence of inhaled corticosteroids.** 2010 ACCP Meeting; Baltimore, MD.
 27. Weber B, Goyal N, Hochhaus G. **Simulation-based evaluation of tmax as a pharmacokinetic parameter to assess bioequivalence of inhaled corticosteroids.** 23rd Annual Research Showcase and Awards Recognition Day at University of Florida; Gainesville, FL.
 28. Kandala B, Weber B, Hochhaus G. **Clinical Trial Simulations Using an Improved Inhalation Model to Evaluate the Potential of Pharmacokinetic Studies in Establishing Bioequivalence of Inhaled Corticosteroids.** 2010 APPS Annual Meeting; New Orleans, LA.
 29. Weber B, Wu K, Blomgren A, Ekholm K, Edsbaecker S, Hochhaus G. **Effect of protein binding on pulmonary corticosteroid receptor occupancy.** 7th Retrometabolism Based Drug Design and Targeting Conference; Orlando, FL.
 30. Goyal N, Weber B, Hochhaus G. **Bioequivalence of Inhaled Corticosteroids - A Pharmacokinetic Approach.** 7th Retrometabolism Based Drug Design and Targeting Conference; Orlando, FL.
-

Awards & Recognitions

- Recipient of **Outstanding Young Alumni Award “40 Gators Under 40”**, April 2019, University of Florida, Gainesville, Florida
- **Innovation Unit Generation Y Representative** at Annual Baden Baden Conference, March 2018, Boehringer Ingelheim, Baden Baden, Germany
- Recipient of inaugural **Val Stella Football Award**, GPEN 2012 Meeting, Monash University, Melbourne, Australia

- Recipient of **Teaching Assistant Recognition Award** (Teaching Assistant of the Year), April 2012, College of Pharmacy, University of Florida, Gainesville, FL
 - Recipient of **Certificate of Outstanding Academic Achievement** at 16th Annual International Student Awards Ceremony, November 2010, International Center & College of Pharmacy, University of Florida, Gainesville, FL
 - Recipient of **Certificate of Outstanding Achievement**, April 2010, International Center, University of Florida, Gainesville, FL
 - **Winner of poster competition (Ph.D. students)** at 23rd Annual Research Showcase and Awards Recognition Day, February 2010, University of Florida, Gainesville, Florida
 - Recipient of the 2010 **AAPS Clinical Pharmacology and Translational Research travel award**
-

Teaching Experience

- **Model-based meta-analysis to replace a head-to-head clinical trial in type 2 diabetes mellitus**, Model-Informed Drug Development Class, University of Florida, 2020
 - **POPPK analysis in NONMEM for beginners**, Hands-on Seminar, University of Florida, 2014
 - **Time-to-event analysis in NONMEM and R with focus on PKPD applications**, One-day Workshop, University of Florida, 2014
 - **R for Pharmacometrics**, Lecture Series, University of Florida, 2012
 - **R for Pharmacometrics - Non-compartmental analysis, two-stage approach and non-linear mixed effects approach**, Hands-on Seminar, University of Florida, 2012
 - **POPPK analysis using the Bayesian approach**, Hands-on Seminar, University of Florida, 2012
 - **Dose Optimization I and II - Basic Theoretical and Applied Pharmacokinetics**, Teaching Assistant, University of Florida, 2009-2013
-

Professional Activities & Memberships

- Invited reviewer for the British Journal of Clinical Pharmacology, AAPS Journal, Journal of Clinical Pharmacology, CPT: Pharmacometrics & Systems Pharmacology, European Journal of Pharmaceutical Sciences, Pharmacology Research & Perspectives, Pharmaceutical Research and Simulation
- American Society for Clinical Pharmacology & Therapeutics (ASCPT)
- International Society of Pharmacometrics (ISoP)
- Deutsche Pharmazeutische Gesellschaft (DPhG)